Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 939 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urinary Bladder Neoplasm Clear all
Completed Phase 1Phase 2 Interventional Results available

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

NCT05259696
View directory record Official record
Conditions
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
Interventions
E-602, Cemiplimab
Biological
Lead sponsor
Palleon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 31, 2026, 10:52 PM EDT
Recruiting Not applicable Interventional

Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy

NCT07662824
View directory record Official record
Conditions
Cervical Carcinoma, Endometrial Carcinoma, Overactive Bladder, Voiding Disorders
Interventions
Educational Intervention, Interview, Flyte Medical Device Usage and Evaluation, Questionnaire Administration, Referral
Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 31, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

NCT01489813
View directory record Official record
Conditions
Bladder Cancer
Interventions
Genistein, Sugar pill
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 31, 2026, 10:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Addressing Barriers to Palliative Care Use in Bladder Cancer

NCT04598724
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer Stage II, Bladder Cancer Stage III, Bladder Cancer Stage IV
Interventions
Surveys
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Oct 31, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

NCT00004223
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
docetaxel, gemcitabine hydrochloride
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
73
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 31, 2026, 10:52 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

NCT03047213
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Sapanisertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
20
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 31, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

R115777 in Treating Patients With Advanced Bladder Cancer

NCT00006376
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
chemotherapy, tipifarnib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
San Francisco, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 31, 2026, 10:52 PM EDT
Completed Phase 1 Interventional Results available

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

NCT02315066
View directory record Official record
Conditions
Neoplasms
Interventions
PF-04518600, PF-04518600 plus PF-05082566
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 31, 2026, 10:52 PM EDT
Recruiting Not applicable Interventional

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

NCT06511141
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
Interventions
Axonics SNM System
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 10:52 PM EDT
Terminated Phase 2 Interventional Results available

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

NCT01118351
View directory record Official record
Conditions
Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay, light microscopy, laboratory biomarker analysis
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 31, 2026, 10:52 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue

NCT02379429
View directory record Official record
Conditions
Bladder Cancer, Urinary Tract Cancer, Urothelial Cancer, Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 10:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

NCT02554812
View directory record Official record
Conditions
Advanced Cancer
Interventions
Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
57
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 31, 2026, 10:52 PM EDT
Recruiting No phase listed Observational

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

NCT07309445
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 10:52 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer

NCT04039867
View directory record Official record
Conditions
Carcinoma, Transitional Cell
Interventions
Oxaliplatin with Gemcitabine
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 31, 2026, 10:52 PM EDT
Terminated No phase listed Observational

A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

NCT01314664
View directory record Official record
Conditions
Bladder Cancer, CIS
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Phoenix, Arizona • Hialeah, Florida • Vero Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 31, 2026, 10:52 PM EDT
Not yet recruiting No phase listed Observational

Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)

NCT07893509
View directory record Official record
Conditions
NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
Interventions
This is a non-interventional, observational, prospective study.
Other
Lead sponsor
Bladder Cancer Advocacy Network
Other
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 10:52 PM EDT
Completed Phase 3 Interventional

Eflornithine in Treating Patients With Bladder Cancer

NCT00003814
View directory record Official record
Conditions
Bladder Cancer
Interventions
eflornithine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
61
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 31, 2026, 10:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

NCT02552121
View directory record Official record
Conditions
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer (NSCLC)
Interventions
Tisotumab vedotin (HuMax-TF-ADC)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 31, 2026, 10:52 PM EDT
Active, not recruiting Phase 1 Interventional

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

NCT05768347
View directory record Official record
Conditions
Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma
Interventions
Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 31, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

NCT01328574
View directory record Official record
Conditions
Urothelial Carcinoma, Ureteral Neoplasms, Ureter Cancer, Neoplasm, Ureteral, Cancer of the Ureter
Interventions
TRC105
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 31, 2026, 10:52 PM EDT
Not listed Phase 1 Interventional

Cardiac Safety Assessment Study of Picoplatin in Solid Tumors

NCT00710697
View directory record Official record
Conditions
Solid Tumors
Interventions
Picoplatin
Drug
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Oct 31, 2026, 10:52 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Genetic Susceptibility to Bladder Cancer

NCT00848289
View directory record Official record
Conditions
Bladder Cancer
Interventions
Interviews
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
6,086 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 31, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

NCT00186277
View directory record Official record
Conditions
Bladder Cancer
Interventions
Oxaliplatin, Taxotere
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2011 · Synced Oct 31, 2026, 10:52 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT07090499
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
PF-08046876, Pembrolizumab, Cisplatin, Carboplatin
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 10:52 PM EDT